AstraZeneca Gets CDSCO Nod For Lung Cancer Drug

New Delhi: AstraZeneca India Pharma on Thursday said it has received approval from the Central Drugs Standard Control Organisation (CDSCO) for Osimertinib tablets in strength of 40mg and 80mg.

The approval marks a critical step forward with Osimertinib as monotherapy in the treatment of patients with locally advanced, unresectable (Stage III) non-small cell lung cancer, it added.

This new indication represents a first-in-class treatment option in a setting for EGFR-mutated NSCLC post-chemoradiation. “With Osimertinib’s approval for this additional indication, we are reaching a significant milestone,” its Country President & MD Sanjeev Panchal said.